CelLBxHealth (AIM:CLBX), a specialist in circulating tumour cell (CTC) technology used in cancer research, drug development and clinical oncology, held its Annual General Meeting on Tuesday in Guildford.
The AIM-listed company reiterated that it remains on track to deliver revenues of at least £2.1 million for the 2026 financial year, a 50% increase on 2025.
Executive Chairman Jan Groen told shareholders that "nothing fundamental has changed within the core of our business and the commercial opportunity for the Company remains significant."
Groen said the company's focus remains on disciplined execution and converting its commercial pipeline into sustainable revenue growth.
